Affinage

IGF2BP2

Insulin-like growth factor 2 mRNA-binding protein 2 · UniProt Q9Y6M1

Length
599 aa
Mass
66.1 kDa
Annotated
2026-06-10
100 papers in source corpus 41 papers cited in narrative 41 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGF2BP2 (IMP-2) is a sequence- and modification-specific RNA-binding protein that operates as a post-transcriptional regulatory hub, predominantly acting as an N6-methyladenosine (m6A) 'reader' that binds methylated transcripts at CDS, stop-codon, or 3'UTR regions to control their stability and translation (PMID:31230592, PMID:35417191, PMID:34980207). Its canonical output is target-mRNA protection: by recognizing m6A marks written by METTL3/METTL14, IGF2BP2 shields transcripts such as SOX2, FEN1, Slug, TAB3, and NLRP3 from degradation, thereby sustaining programs in cancer proliferation, EMT/metastasis, and inflammation (PMID:31230592, PMID:33224879, PMID:34980207, PMID:35417191, PMID:38218935). Beyond stabilization, IGF2BP2 can enhance translation initiation of m6A-modified targets — for CDK6 it does so without altering mRNA levels by recruiting EIF4A1, and it similarly drives translation of Pdx1, YAP, and c-MYC (PMID:37983610, PMID:33705986, PMID:34309973, PMID:40591591). IGF2BP2 also operates as a negative regulator in defined contexts, recruiting the XRN2 nuclease or the CCR4-NOT deadenylase to destabilize specific transcripts (ATP6V1A, Fzd8) depending on its modification state and signaling input (PMID:36322753, PMID:36219823). This functional switching is set by post-translational control: SIRT1-regulated acetylation toggles IGF2BP2 between mRNA protection and degradation (PMID:36322753), SUMO1-mediated SUMOylation at K497/K505/K509 blocks proteasomal turnover (PMID:34345216), and competing E3 ligases (FBW7/GSK3β, TRIM25, TRIM15) drive its ubiquitination and degradation (PMID:38281999, PMID:39080693, PMID:38657551). A large family of lncRNAs and circRNAs (LINRIS, circEZH2, circRHBDD1, LCAT1, circHIPK3, circRNA-BISC) bind IGF2BP2 to block its ubiquitination, nucleate it into phase-separated condensates, or competitively inhibit its translational activity (PMID:31791342, PMID:35773744, PMID:39080693, PMID:39041323, PMID:40591591). Genetically, IGF2BP2 is required for diverse developmental and metabolic programs, including zygotic genome activation at the 2-cell stage, pancreatic β-cell proliferation and insulin secretion, hematopoietic stem cell mitochondrial metabolism and self-renewal, and cardiomyocyte homeostasis, where its forced overexpression produces reversible dilated cardiomyopathy (PMID:31406667, PMID:33705986, PMID:35231105, PMID:38052926). Earlier work established its role in muscle, where it binds PINCH-2, MURF-3, Myf5, and cyclin A2 transcripts and supports microtubule stabilization and myoblast function (PMID:20956565, PMID:27672022).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2010 High

    Established IGF2BP2 as a direct mRNA-binding regulator of protein output before its m6A-reader role was known, anchoring its function in cytoskeletal and motility control.

    Evidence Gel-shift (EMSA) and gain/loss-of-function in myoblasts identifying PINCH-2 and MURF-3 as bound transcripts and a requirement for microtubule stabilization

    PMID:20956565

    Open questions at the time
    • No m6A dependency tested at this stage
    • Mechanism of stabilization vs translation control not distinguished
  2. 2016 Medium

    Showed IGF2BP2 protects target mRNAs from miRNA-mediated decay and acts downstream of upstream regulators, broadening its role to competitive post-transcriptional control.

    Evidence shRNA/overexpression studies of RAF1 vs miR-195 in colorectal cancer, and rescue experiments placing IGF2BP2 downstream of HMGB2 for Myf5/cyclin A2 in myoblasts

    PMID:27153315 PMID:27672022

    Open questions at the time
    • Direct binding not always confirmed by orthogonal biophysical assays
    • m6A involvement not addressed
  3. 2019 High

    Defined IGF2BP2 as a bona fide m6A reader that stabilizes methylated transcripts and ncRNAs, establishing its central modern mechanism.

    Evidence MeRIP-seq, reciprocal RNA pull-down/RIP, and m6A-site mutagenesis for SOX2 mRNA (CDS) and DANCR lncRNA downstream of METTL3 in colorectal and pancreatic cancer

    PMID:31230592 PMID:31804607

    Open questions at the time
    • Whether reading is stabilization or translation was not generalized
    • Reader specificity over IGF2BP1/3 not addressed
  4. 2019 High

    Identified the first layer of IGF2BP2 protein-stability control by lncRNA, linking its abundance to glycolytic and developmental programs.

    Evidence RNA pull-down/RIP and ubiquitination assays showing LINRIS blocks K139 ubiquitination and autophagy-lysosome degradation; maternal conditional KO showing 2-cell arrest and IGF2 rescue

    PMID:31406667 PMID:31791342

    Open questions at the time
    • Identity of the K139 E3 ligase not established here
    • Direct targets driving ZGA arrest only partially defined
  5. 2021 High

    Resolved post-translational regulation of IGF2BP2 by SUMOylation and demonstrated m6A-dependent translational (not just stability) control of a physiological target.

    Evidence In vitro SUMOylation, Co-IP, and lysine mutagenesis (K497/K505/K509, SENP1 eraser); β-cell-specific Imp2 KO with RIP and m6A-dependent Pdx1 translation assays

    PMID:33705986 PMID:34345216

    Open questions at the time
    • Interplay between SUMOylation and ubiquitination not quantified
    • Generality of translational enhancement across targets unresolved
  6. 2022 High

    Established IGF2BP2 as a switchable regulator that can also degrade transcripts and recruit distinct effectors, and confirmed it as a druggable cancer target.

    Evidence SIRT1-acetylation/XRN2 recruitment switch on ATP6V1A; CCR4-NOT/mTOR-dependent Fzd8 degradation in MSCs; EIF4A1 recruitment for CDK6 translation; small-molecule CWI1-2 and biophysically validated inhibitors

    PMID:35023719 PMID:36219823 PMID:36306790 PMID:36322753 PMID:37983610

    Open questions at the time
    • Determinants choosing protection vs degradation per transcript incompletely mapped
    • Direct vs indirect effector recruitment not structurally resolved
  7. 2022 High

    Expanded the regulatory network controlling IGF2BP2 abundance through multiple E3 ligases and circRNA/lncRNA shields, and demonstrated feedback loops.

    Evidence Co-IP/ubiquitination assays for FBW7-GSK3β and TRIM25 (blocked by circRHBDD1); circEZH2 and circRUNX1 stabilization of IGF2BP2; SLC7A5-H3K4me3 positive feedback at the IGF2BP2 promoter

    PMID:35773744 PMID:36522683 PMID:38281999 PMID:39080693

    Open questions at the time
    • Relative contribution of competing E3 ligases in vivo unknown
    • Stoichiometry of circRNA shielding not defined
  8. 2023 High

    Demonstrated genetic requirements of IGF2BP2 in stem-cell metabolism and cardiac homeostasis, showing dose- and reversibility-dependent pathology.

    Evidence Igf2bp2 KO mice showing impaired HSC oxidative metabolism and repopulation; inducible cardiomyocyte transgenic mice with reversible dilated cardiomyopathy

    PMID:35231105 PMID:38052926

    Open questions at the time
    • Direct mitochondrial/sarcomeric mRNA targets not fully enumerated
    • Mechanism linking IGF2BP2 to mitochondrial fragmentation unresolved
  9. 2024 High

    Defined IGF2BP2 as a driver of immune evasion and inflammation across tissues, and established sequence-specific, paralog-selective circRNA antagonism via phase separation.

    Evidence MeRIP/RIP and in vivo models linking IGF2BP2 to NLRP3, PD-L1 (via SGMS2/lipid rafts and matrix stiffness), TLR4; circHIPK3 and circRNA-BISC motif-specific binding and condensate formation

    PMID:38218935 PMID:38657551 PMID:39041323 PMID:40158738 PMID:40591591

    Open questions at the time
    • Structural basis of condensate assembly not solved
    • Whether phase separation alters target selectivity globally unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How IGF2BP2 integrates competing post-translational modifications, condensate formation, and m6A reading to deterministically select between stabilizing, degrading, or translationally enhancing a given transcript remains unresolved.
  • No unified structural model of the reader-effector interface
  • Genome-wide rules predicting protection vs degradation are lacking
  • Physiological hierarchy among acetylation, SUMOylation, and ubiquitination not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 7 GO:0045182 translation regulator activity 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005829 cytosol 2
Pathway
R-HSA-1643685 Disease 5 R-HSA-8953854 Metabolism of RNA 5 R-HSA-168256 Immune System 4
Partners
CCR4-NOTEIF4A1FBW7SENP1SIRT1TRIM15TRIM25XRN2

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 IGF2BP2 acts as an m6A 'reader' that recognizes and binds m6A-modified SOX2 mRNA specifically at coding sequence (CDS) regions, preventing SOX2 mRNA degradation and thereby maintaining SOX2 expression in colorectal cancer cells downstream of METTL3. MeRIP-seq, RNA pull-down, RNA immunoprecipitation, RNA stability assay Molecular cancer High 31230592
2019 LncRNA LINRIS binds IGF2BP2 and blocks K139 ubiquitination of IGF2BP2, preventing its degradation through the autophagy-lysosome pathway (ALP), thereby stabilizing IGF2BP2 protein and sustaining MYC-mediated glycolysis in colorectal cancer cells. RNA pull-down, RIP assay, ubiquitination assay, autophagy-lysosome pathway inhibition experiments Molecular cancer High 31791342
2019 IGF2BP2 binds m6A-modified lncRNA DANCR (with the critical adenosine at position 664 identified by mutagenesis) and stabilizes DANCR RNA, promoting cancer stemness-like properties in pancreatic cancer. In vivo RNA precipitation, reciprocal RNA immunoprecipitation, mutagenesis assay of m6A site Cell death and differentiation High 31804607
2022 IGF2BP2 promotes AML development and leukemia stem/initiation cell self-renewal by regulating expression of MYC, GPT2, and SLC1A5 in the glutamine metabolism pathway in an m6A-dependent manner; inhibition by small-molecule CWI1-2 shows anti-leukemia effects. m6A-dependent target gene regulation assays, small-molecule inhibitor (CWI1-2) in vitro and in vivo, loss-of-function with defined phenotypic readouts Cancer cell High 36306790
2022 IGF2BP2 binds m6A-modified TAB3 mRNA at stop codon regions, enhancing TAB3 mRNA stability; this is downstream of METTL3-mediated m6A modification and promotes renal inflammation. MeRIP-seq, RIP assay, RNA stability assay, conditional METTL3 knockout mouse model Science translational medicine High 35417191
2022 IGF2BP2 recognizes m6A-modified EphA2 and VEGFA mRNAs (written by METTL3) and prevents their degradation, promoting vasculogenic mimicry in colorectal cancer via PI3K/AKT/mTOR and ERK1/2 signaling. CRISPR/Cas9 knockdown, RNA-seq, RIP assay, m6A reader binding confirmation Cell death & disease Medium 35595748
2020 IGF2BP2 directly recognizes and binds the m6A site on FEN1 mRNA, enhancing FEN1 mRNA stability and promoting hepatocellular carcinoma proliferation in vitro and in vivo. RIP assay, RNA stability assay, overexpression and knockdown in vitro and in vivo Frontiers in oncology Medium 33224879
2022 IGF2BP2 stabilizes m6A-modified Slug mRNA by binding the m6A site in the CDS region of Slug, promoting EMT and lymphatic metastasis in head and neck squamous cell carcinoma. RIP, MeRIP, luciferase reporter assay, mRNA stability assay, in vivo lymphatic metastasis model Journal of experimental & clinical cancer research High 34980207
2010 IMP-2 (IGF2BP2) directly binds the mRNAs of PINCH-2 and MURF-3 (confirmed by gel shift experiments), regulating their protein expression; upregulation of PINCH-2 in IMP-2-depleted myoblasts is the key event responsible for decreased cell motility; IMP-2 is also required for microtubule stabilization. Gel shift (EMSA), gain- and loss-of-function assays, transcript binding analysis Molecular and cellular biology High 20956565
2022 CircEZH2 interacts with IGF2BP2 and blocks its ubiquitination-dependent degradation, stabilizing IGF2BP2; additionally, the circEZH2/IGF2BP2 complex enhances CREB1 mRNA stability in colorectal cancer. RNA pulldown, mass spectrometry, RIP, MeRIP-seq, western blot, luciferase reporter assays Molecular cancer Medium 35773744
2021 SUMOylation of IGF2BP2 at lysine residues K497, K505, and K509 (primarily via SUMO1) increases IGF2BP2 protein stability by blocking its ubiquitin-proteasome degradation; this modification can be reversed by SENP1. SUMOylated IGF2BP2 enhances OIP5-AS1 lncRNA stability and promotes glioma vasculogenic mimicry. Ni2+-NTA agarose bead pull-down, Co-IP, western blot, in vitro SUMOylation assay, immunoprecipitation, immunofluorescence, RIP, luciferase reporter assays International journal of biological sciences High 34345216
2022 IGF2BP2 binds to the 3'UTR of the ATP6V1A transcript and, when acetylated (due to low SIRT1 expression), recruits the XRN2 nuclease to mediate ATP6V1A transcript degradation. When SIRT1 deacetylates IGF2BP2, binding occurs but degradation does not. Thus, SIRT1-regulated acetylation of IGF2BP2 switches its function from mRNA protection to mRNA degradation. RNA binding assays, SIRT1 deacetylation assay, XRN2 recruitment assay, mRNA stability measurement, SIRT1 knockdown Proceedings of the National Academy of Sciences of the United States of America High 36322753
2021 IMP2/IGF2BP2 directly binds Pdx1 mRNA and stimulates its translation in an m6A-dependent manner; additionally, IMP2 orchestrates IGF2-AKT-GSK3β-PDX1 signaling to stabilize PDX1 protein, promoting pancreatic β-cell proliferation and insulin secretion. Pancreatic β-cell-specific Imp2 knockout mice, RIP assay, m6A-dependent translation assay, signaling pathway analysis Molecular metabolism High 33705986
2018 Airn lncRNA binds IGF2BP2 (identified by RNA pull-down/mass spectrometry) and controls translation of several IGF2BP2-target genes in cardiomyocytes; silencing Airn reduces binding of IGF2BP2 to other mRNAs and reduces IGF2BP2 protein translation. RNA pull-down followed by mass spectrometry, further RIP assays, siRNA silencing Circulation research Medium 29483092
2016 IGF2BP2 regulates RAF1 expression in colorectal cancer cells by protecting RAF1 mRNA from degradation by miR-195, functioning as a post-transcriptional regulatory factor that interferes with miRNA-mediated mRNA degradation. Overexpression and shRNA-mediated silencing, molecular function analyses FEBS letters Medium 27153315
2016 IGF2BP2 is a downstream target of HMGB2 in myoblasts; IGF2BP2 binds mRNAs of Myf5 and cyclin A2, enhancing Myf5 translation and cyclin A2 mRNA stabilization, respectively. Overexpression of IGF2BP2 partially rescues Myf5 and cyclin A2 protein levels upon HMGB2 depletion. Knockdown/overexpression rescue experiments, western blot, in vivo satellite cell depletion model Journal of cell science Medium 27672022
2019 Maternal deletion of Igf2bp2 (IMP2) in mouse embryos causes developmental arrest at the 2-cell stage; IMP2 regulates expression of Ccar1 and Rps14 required for zygotic genome activation, and IGF2 (a known IMP2 target) addition rescues developmental competence. Maternal-specific conditional knockout mice, transcriptomics, proteomics, embryo culture rescue assays Advanced science High 31406667
2022 IGF2BP2 promotes cell cycle progression in TNBC by recognizing m6A-modified CDK6 mRNA and enhancing its translation initiation (not mRNA stability) by recruiting EIF4A1; this is dependent on m6A modification. m6A-dependent translation assay, RIP, mRNA stability assay (showing no effect), EIF4A1 co-immunoprecipitation, CDK6 reporter assays Advanced science High 37983610
2022 FBW7 (ubiquitin ligase) works together with GSK3β kinase to recognize and degrade IGF2BP2 through ubiquitination; conversely, IGF2BP2 enhances SLC7A5 mRNA stability and translation through m6A modification, with SLC7A5-mediated methionine transport feeding back to increase H3K4me3 at the IGF2BP2 promoter, forming a positive feedback loop promoting lung cancer radioresistance. Ubiquitination assays, Co-IP, ChIP-qPCR, RIP, MeRIP-qPCR, RNA pull-down Journal of experimental & clinical cancer research High 38281999
2023 IGF2BP2 promotes liver cancer progression by recognizing and binding m6A-modified FLT4 mRNA (secreted via exosomes to endothelial cells), improving FLT4 RNA stability and activating the PI3K-Akt signaling pathway to promote angiogenesis. Single-cell RNA sequencing, exosome isolation, m6A modification assay, PI3K-Akt pathway analysis Molecular cancer Medium 37353784
2022 IGF2BP2 recognizes m6A modification sites in IGF1R mRNA, increases IGF1R expression, and activates the RhoA-ROCK pathway to promote gastric cancer progression; this was confirmed by RIP and RNA pull-down assays. RIP assay, RNA pull-down, qRT-PCR, western blot, in vitro and in vivo functional assays Cellular signalling Medium 35306138
2023 IGF2BP2 promotes glycolysis and hepatic stellate cell activation by stabilizing ALDOA (Aldolase A) mRNA via m6A-binding, generating lactate that drives histone lactylation to sustain the activated phenotype of hepatic stellate cells. m6A binding assay, mRNA stability assay, glycolysis measurement, histone lactylation analysis, loss-of-function experiments Cell death & disease Medium 38443347
2022 IGF2BP2 binds to circRUNX1 and prevents its degradation; IGF2BP2-stabilized circRUNX1 sponges miR-449b-5p to upregulate FOXP3, facilitating esophageal squamous cell carcinoma growth and metastasis. RIP assay, RNA immunoprecipitation, RNA sequencing, dual-luciferase reporter assays, rescue experiments Journal of experimental & clinical cancer research Medium 36522683
2022 CircRHBDD1 binds to IGF2BP2 and disrupts the interaction between E3 ligase TRIM25 and IGF2BP2, inhibiting IGF2BP2 ubiquitination and degradation; stabilized IGF2BP2 then enhances PD-L1 mRNA stability through m6A modification to promote immune escape in gastric cancer. RNA immunoprecipitation, Co-IP, meRIP analysis, ubiquitination assay, flow cytometry Journal of translational medicine Medium 39080693
2024 METTL14-mediated m6A modification stabilizes GluN2A subunit (NMDAR) expression via IGF2BP2 in DRG neurons; METTL14-mediated m6A facilitates synaptic plasticity and pain hypersensitivity through this IGF2BP2-dependent mechanism. Dot blotting, immunofluorescence, gain/loss-of-function, behavioral assays, RIP (implied from m6A-IGF2BP2-dependent mechanism) The Journal of clinical investigation Medium 38319733
2024 METTL14-mediated m6A modification of NLRP3 mRNA is recognized by IGF2BP2, which stabilizes NLRP3 mRNA; IGF2BP2 knockdown diminishes LPS-induced acute lung injury in mice by downregulating NLRP3 expression. MeRIP, RIP assay, in vitro macrophage experiments, mouse ALI model with IGF2BP2 knockdown Cell death & disease High 38218935
2022 Igf2bp2 deletion in young mice reduces oxidative metabolism and impairs colony formation and HSC repopulation capacity, mimicking aging-related changes; Igf2bp2-deficient aged mice show amelioration of aging-associated HSC expansion and myeloid skewing, indicating Igf2bp2 regulates mitochondrial metabolism and stemness of young HSCs. Igf2bp2 knockout mouse model, RNA sequencing, colony formation assays, bone marrow transplantation/repopulation assays Blood High 35231105
2023 LCAT1 lncRNA physically interacts with and stabilizes IGF2BP2 by preventing its degradation via autolysosomes; the LCAT1/IGF2BP2 complex then increases CDC6 mRNA levels by stabilizing CDC6 mRNA in an m6A-dependent manner, promoting lung cancer progression. RNA pulldown, Co-IP, RIP, m6A-dependent mRNA stability assay Cell death & disease Medium 36257938
2023 IGF2BP2 overexpression in cardiomyocytes leads to dilated cardiomyopathy (DCM) with downregulation of sarcomeric and mitochondrial proteins and fragmented mitochondria; downregulating the IGF2BP2 transgene after 2 weeks rescues DCM, demonstrating reversible pathological role. Conditional inducible transgenic mouse model, cardiac phenotyping, proteomics Communications biology High 38052926
2023 IMP2/IGF2BP2 binds Wnt receptor Fzd8 mRNA and promotes its degradation by recruiting the CCR4-NOT deadenylase complex in an mTOR-dependent manner in mesenchymal stem cells, controlling adipogenic commitment and white adipose tissue homeostasis. Conditional MSC-specific Imp2 knockout mice, RIP assay, mRNA stability analysis, mTOR pathway inhibition Diabetes High 36219823
2024 First small-molecule inhibitors of IGF2BP2/IMP2 were identified and validated: compounds from benzamidobenzoic acid and ureidothiophene classes were confirmed to bind IMP2 by fluorescence polarization assay, thermal shift assay, and saturation-transfer difference NMR, and showed biological activity reducing tumor cell proliferation in vitro and in xenograft models. Fluorescence polarization assay, thermal shift assay, saturation-transfer difference NMR, 2D/3D cell culture, zebrafish xenotransplant in vivo ACS chemical biology High 35023719
2022 Circ-TNPO3 directly binds IGF2BP2 protein (via RNA pull-down and RIP), and this interaction destabilizes SERPINH1 mRNA, suppressing ccRCC metastasis; rescue experiments confirmed that IGF2BP2/SERPINH1 axis mediates the tumor-suppressive function of circ-TNPO3. RNA pull-down, RNA immunoprecipitation, RIP, FISH, rescue assays, in vitro and in vivo models Clinical and translational medicine Medium 35876041
2024 IGF2BP2 regulates the stability of GSTM5 mRNA in fibroblast-like synoviocytes, and the IGF2BP2-GSTM5 axis controls inflammatory responses and MMP9/MMP13 expression in rheumatoid arthritis; intra-articular AAV-mediated IGF2BP2 overexpression relieved arthritis in a CIA rat model. RNA sequencing, RIP (implied), in vivo CIA rat model with AAV overexpression, mRNA stability assay Cell death discovery Medium 38702323
2021 Let-7e-5p directly downregulates Igf2bp2 expression at the mRNA and protein level in C2C12 myotube cells, inhibiting myosin heavy chain expression and impairing mitochondrial function and glucose uptake, causing muscle atrophy. microRNA overexpression/knockdown, RT-PCR, western blot in C2C12 myotubes Frontiers in endocrinology Low 35002969
2024 circHIPK3 contains an 11-mer motif that constitutes a strong IGF2BP2 binding site; circHIPK3 can nucleate multiple copies of IGF2BP2, potentially via phase separation, to produce IGF2BP2 condensates, sequestering IGF2BP2 as a competing endogenous RNA and regulating STAT3 mRNA stability via IGF2BP2. eCLIP dataset mining, RIP assay, absolute copy number quantification, RNA sequencing, phase separation analysis eLife High 39041323
2024 High matrix stiffness in pancreatic cancer stabilizes IGF2BP2, which promotes sphingomyelin synthesis via SGMS2 upregulation; this pathway facilitates PD-L1 localization on membrane lipid rafts, enhancing immune evasion. MeRIP, RIP, RNA pull-down, single-cell RNA-sequencing, flow cytometry, multiplex IHC, humanized mouse models, PDAC organoids Gastroenterology High 40158738
2024 TRIM15 ubiquitinates IGF2BP2, which enhances IGF2BP2's function in phase separation and maintenance of TLR4 mRNA stability in pancreatic cancer; IGF2BP2 combines with TLR4 to inhibit its mRNA degradation. Transcriptomics, proteomics, Co-IP, ubiquitination assay, in vivo orthotopic mouse model Biochimica et biophysica acta. Molecular basis of disease Medium 38657551
2024 IGF2BP2 directly interacts with CD5L and CD36 mRNA (confirmed by RIP), stabilizing their expression; in osteoclastogenesis during periodontitis, IGF2BP2 regulates osteoclast differentiation via CD36 and CD5L, and its deficiency exacerbates early-stage inflammation but reduces osteoclast differentiation at later stages. RIP assay, AAV-mediated knockdown, ligature-induced periodontitis mouse model, overexpression rescue experiments Journal of dental research Medium 38193302
2025 A circular RNA (circRNA-BISC) contains a 'CAC-linker-XGGX' motif that specifically binds IGF2BP2 (but not IGF2BP1 or IGF2BP3), inhibiting IGF2BP2-mediated translation enhancement of c-MYC mRNA and overcoming BETi resistance in TNBC. RIP-Seq, RNA immunoprecipitation, in vitro transcribed circRNA functional assays, cell and in vivo BETi-resistant TNBC models Proceedings of the National Academy of Sciences of the United States of America High 40591591
2022 IGF2BP2 promotes YAP mRNA translation by recognizing its m6A modification in colorectal cancer; YAP subsequently promotes TEAD4 enrichment at the ErbB2 promoter to upregulate ErbB2 expression. RIP assay, m6A recognition, promoter enrichment assay Cancer science Medium 34309973
2024 IGF2BP2 stabilizes m6A-modified FOSL1 mRNA in trophoblast cells in an IGF2BP2-dependent manner downstream of METTL3; elevated FOSL1 inhibits trophoblast invasion, contributing to fetal growth restriction. MeRIP-seq, RNA-seq, RIP assay, mRNA stability assay, in vivo FGR mouse model FASEB journal Medium 39565355

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma. Molecular cancer 654 31230592
2019 LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular cancer 407 31791342
2022 The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer cell 275 36306790
2019 IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader. Cell death and differentiation 274 31804607
2022 Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms. Science translational medicine 262 35417191
2022 EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling. Cancer research 182 34965937
2021 The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer cell international 179 33568150
2022 m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell death & disease 161 35595748
2022 CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of m6A-modified CREB1 mRNA. Molecular cancer 136 35773744
2022 LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Journal of hematology & oncology 134 35526050
2020 IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism. Frontiers in oncology 128 33224879
2022 HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m6A-MYC expression. International journal of biological sciences 118 35002506
2022 RNA N6-methyladenosine reader IGF2BP2 promotes lymphatic metastasis and epithelial-mesenchymal transition of head and neck squamous carcinoma cells via stabilizing slug mRNA in an m6A-dependent manner. Journal of experimental & clinical cancer research : CR 109 34980207
2023 m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma. Molecular cancer 102 37353784
2020 The Diverse Functions of IMP2/IGF2BP2 in Metabolism. Trends in endocrinology and metabolism: TEM 97 32586768
2016 IGF2BP2 promotes colorectal cancer cell proliferation and survival through interfering with RAF-1 degradation by miR-195. FEBS letters 84 27153315
2019 RNA-Binding Protein IGF2BP2/IMP2 is a Critical Maternal Activator in Early Zygotic Genome Activation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 77 31406667
2024 The m6A reader IGF2BP2 regulates glycolytic metabolism and mediates histone lactylation to enhance hepatic stellate cell activation and liver fibrosis. Cell death & disease 73 38443347
2022 Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA. Clinical and translational medicine 68 35876041
2021 IGF2BP2 promotes the progression of colorectal cancer through a YAP-dependent mechanism. Cancer science 68 34309973
2022 First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy. ACS chemical biology 57 35023719
2021 RNA m6A reader IMP2/IGF2BP2 promotes pancreatic β-cell proliferation and insulin secretion by enhancing PDX1 expression. Molecular metabolism 52 33705986
2021 microRNA-320b suppresses HNF4G and IGF2BP2 expression to inhibit angiogenesis and tumor growth of lung cancer. Carcinogenesis 50 33758932
2021 SUMOylation of IGF2BP2 promotes vasculogenic mimicry of glioma via regulating OIP5-AS1/miR-495-3p axis. International journal of biological sciences 49 34345216
2010 Role of the RNA-binding protein IMP-2 in muscle cell motility. Molecular and cellular biology 49 20956565
2023 IGF2BP2 Drives Cell Cycle Progression in Triple-Negative Breast Cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 47 37983610
2022 IGF2BP2-induced circRUNX1 facilitates the growth and metastasis of esophageal squamous cell carcinoma through miR-449b-5p/FOXP3 axis. Journal of experimental & clinical cancer research : CR 46 36522683
2024 CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer. Journal of translational medicine 42 39080693
2021 RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis. Journal of ovarian research 42 34774079
2024 METTL14-mediated m6A epitranscriptomic modification contributes to chemotherapy-induced neuropathic pain by stabilizing GluN2A expression via IGF2BP2. The Journal of clinical investigation 41 38319733
2022 Age-dependent effects of Igf2bp2 on gene regulation, function, and aging of hematopoietic stem cells in mice. Blood 38 35231105
2024 METTL14 contributes to acute lung injury by stabilizing NLRP3 expression in an IGF2BP2-dependent manner. Cell death & disease 37 38218935
2024 m6A modification of lncRNA ABHD11-AS1 promotes colorectal cancer progression and inhibits ferroptosis through TRIM21/IGF2BP2/ FOXM1 positive feedback loop. Cancer letters 37 38838765
2023 IGF2BP2 promotes colorectal cancer progression by upregulating the expression of TFRC and enhancing iron metabolism. Biology direct 34 37088822
2022 IGF2BP2 promotes gastric cancer progression by regulating the IGF1R-RhoA-ROCK signaling pathway. Cellular signalling 34 35306138
2018 Airn Regulates Igf2bp2 Translation in Cardiomyocytes. Circulation research 33 29483092
2022 IGF2BP2 Induces U251 Glioblastoma Cell Chemoresistance by Inhibiting FOXO1-Mediated PID1 Expression Through Stabilizing lncRNA DANCR. Frontiers in cell and developmental biology 32 35141227
2024 KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma. Journal of experimental & clinical cancer research : CR 31 38443991
2022 IGF2BP2 promotes cancer progression by degrading the RNA transcript encoding a v-ATPase subunit. Proceedings of the National Academy of Sciences of the United States of America 31 36322753
2012 IGF2BP2 and IGF2 genetic effects in diabetes and diabetic nephropathy. Journal of diabetes and its complications 31 22770937
2024 IGF2BP2 promotes cell invasion and epithelial-mesenchymal transition through Src-mediated upregulation of EREG in oral cancer. International journal of biological sciences 30 38250159
2023 IGF2BP2-meidated m6A modification of CSF2 reprograms MSC to promote gastric cancer progression. Cell death & disease 30 37865637
2016 HMGB2 regulates satellite-cell-mediated skeletal muscle regeneration through IGF2BP2. Journal of cell science 30 27672022
2024 FBW7/GSK3β mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer. Journal of experimental & clinical cancer research : CR 29 38281999
2021 IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of long non-coding RNA HAGLR. Pathology, research and practice 29 34340128
2011 Association between IGF2BP2 rs4402960 polymorphism and risk of type 2 diabetes mellitus: a meta-analysis. Archives of medical research 29 21839790
2020 IGF2BP2 Polymorphisms Are Associated with Clinical Characteristics and Development of Oral Cancer. International journal of molecular sciences 27 32784624
2024 IGF2BP2-modified circular RNA circCHD7 promotes endometrial cancer progression via stabilizing PDGFRB and activating JAK/STAT signaling pathway. Cancer gene therapy 26 38778089
2022 IGF2BP2, an RNA-binding protein regulates cell proliferation and osteogenic differentiation by stabilizing SRF mRNA. Journal of cellular physiology 26 36436184
2022 LCAT1 is an oncogenic LncRNA by stabilizing the IGF2BP2-CDC6 axis. Cell death & disease 24 36257938
2025 IGF2BP2: an m6A reader that affects cellular function and disease progression. Cellular & molecular biology letters 23 40205577
2014 Association analysis of IGF2BP2, KCNJ11, and CDKAL1 polymorphisms with type 2 diabetes mellitus in a Moroccan population: a case-control study and meta-analysis. Biochemical genetics 23 24898818
2023 LncRNA MEG3 aggravates adipocyte inflammation and insulin resistance by targeting IGF2BP2 to activate TLR4/NF-κB signaling pathway. International immunopharmacology 22 37348228
2022 IGF2BP2 promotes the progression of ovarian endometriosis by regulating m6A-modified MEIS2 and GATA6. The international journal of biochemistry & cell biology 22 36113831
2022 Hsa_circ_0001756 promotes ovarian cancer progression through regulating IGF2BP2-mediated RAB5A expression and the EGFR/MAPK signaling pathway. Cell cycle (Georgetown, Tex.) 21 35113003
2022 N6-methyladenosine (m6A) reader IGF2BP2 promotes gastric cancer progression via targeting SIRT1. Bioengineered 21 35502827
2022 IGF2BP2 Promotes Epithelial to Mesenchymal Transition and Metastasis through Stabilizing HMGA1 mRNA in Gastric Cancer. Cancers 21 36358799
2024 m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clinical and translational medicine 20 38572589
2023 IGF2BP2 attenuates intestinal epithelial cell ferroptosis in colitis by stabilizing m6A-modified GPX4 mRNA. Cytokine 20 38039694
2022 CircEIF3H-IGF2BP2-HuR scaffold complex promotes TNBC progression via stabilizing HSPD1/RBM8A/G3BP1 mRNA. Cell death discovery 20 35568705
2022 IGF2BP2 promotes pancreatic carcinoma progression by enhancing the stability of B3GNT6 mRNA via m6A methylation. Cancer medicine 20 35908253
2014 Correlation between IGF2BP2 gene polymorphism and the risk of breast cancer in Chinese Han women. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20 25661373
2023 IGF2BP2 promotes glycolysis and hepatocellular carcinoma stemness by stabilizing CDC45 mRNA via m6A modification. Cell cycle (Georgetown, Tex.) 19 37985379
2025 Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism. Gastroenterology 18 40158738
2024 IGF2BP2-m6A-circMMP9 axis recruits ETS1 to promote TRIM59 transcription in laryngeal squamous cell carcinoma. Scientific reports 18 38321126
2024 Hypoxia induced cellular and exosomal RPPH1 promotes breast cancer angiogenesis and metastasis through stabilizing the IGF2BP2/FGFR2 axis. Oncogene 18 39496940
2022 N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis. Genes & diseases 18 37223505
2023 A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer. Molecular cancer 17 37248468
2023 Circular RNA circEYA3 promotes the radiation resistance of hepatocellular carcinoma via the IGF2BP2/DTX3L axis. Cancer cell international 17 38042777
2018 Investigation of IGF1, IGF2BP2, and IGFBP3 variants with lymph node status and esophagogastric junction adenocarcinoma risk. Journal of cellular biochemistry 17 30335898
2023 LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via regulating LRG1 mRNA stability. Cellular signalling 16 37541640
2020 Lack of association between IGF2BP2 rs4402960 polymorphism and gestational diabetes mellitus: a case-control study, meta-analysis and trial sequential analysis. Bioscience reports 16 32662505
2011 IGF2BP2 genetic variation and type 2 diabetes: a global meta-analysis. DNA and cell biology 16 22032244
2025 Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2. Journal of experimental & clinical cancer research : CR 15 40025525
2024 Dual Role of IGF2BP2 in Osteoimmunomodulation during Periodontitis. Journal of dental research 15 38193302
2024 METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms. Molecular and cellular biochemistry 15 38822192
2023 IGF2BP2 promotes lncRNA DANCR stability mediated glycolysis and affects the progression of FLT3-ITD + acute myeloid leukemia. Apoptosis : an international journal on programmed cell death 15 37060505
2023 METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3. Scientific reports 15 37828232
2022 Long noncoding RNA LIPH-4 promotes esophageal squamous cell carcinoma progression by regulating the miR-216b/IGF2BP2 axis. Biomarker research 15 35971159
2023 RNA binding protein IGF2BP2 expression is induced by stress in the heart and mediates dilated cardiomyopathy. Communications biology 14 38052926
2022 miR-96-5p regulates cervical cancer cell resistance to cisplatin by inhibiting lncRNA TRIM52-AS1 and promoting IGF2BP2. The Kaohsiung journal of medical sciences 14 36354205
2025 METTL3/IGF2BP2/IκBα axis participates in neuroinflammation in Alzheimer's disease by regulating M1/M2 polarization of microglia. Neurochemistry international 13 40107503
2024 IGF2BP2 regulates the inflammation of fibroblast-like synoviocytes via GSTM5 in rheumatoid arthritis. Cell death discovery 13 38702323
2022 Novel Association of IGF2BP2 Gene Variants With Altered Risk of Breast Cancer and as Potential Molecular Biomarker of Triple Negative Breast Cancer. Clinical breast cancer 13 36653207
2021 Let-7e-5p Regulates IGF2BP2, and Induces Muscle Atrophy. Frontiers in endocrinology 13 35002969
2025 A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC. Proceedings of the National Academy of Sciences of the United States of America 11 40591591
2024 The IGF2BP2-lncRNA TRPC7-AS1 axis promotes hepatocellular carcinoma cell proliferation and invasion. Cellular signalling 11 38320625
2024 circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA. eLife 11 39041323
2024 M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1. International immunopharmacology 11 39126735
2023 Human T2D-Associated Gene IMP2/IGF2BP2 Promotes the Commitment of Mesenchymal Stem Cells Into Adipogenic Lineage. Diabetes 11 36219823
2024 METTL3 inhibits BMSC apoptosis and facilitates osteonecrosis repair via an m6A-IGF2BP2-dependent mechanism. Heliyon 10 38784565
2024 IGF2BP2-Shox2 axis regulates hippocampal-neuronal senescence to alleviate microgravity-induced recognition disturbance. iScience 10 38812544
2024 FTO/IGF2BP2-mediated N6 methyladenosine modification in invasion and metastasis of thyroid carcinoma via CDH12. Cell death & disease 10 39379360
2024 The RNA binding protein IGF2BP2/IMP2 alters the cargo of cancer cell-derived extracellular vesicles supporting tumor-associated macrophages. Cell communication and signaling : CCS 9 38937789
2024 METTL3 and IGF2BP2 coordinately regulate FOSL1 mRNA via m6A modification, suppressing trophoblast invasion and contributing to fetal growth restriction. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 9 39565355
2023 IGF2BP2-modified UBE2D1 interacts with Smad2/3 to promote the progression of breast cancer. American journal of cancer research 9 37560007
2022 IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma. Bioscience reports 9 36281789
2024 Ubiquitin ligase TRIM15 promotes the progression of pancreatic cancer via the upregulation of the IGF2BP2-TLR4 axis. Biochimica et biophysica acta. Molecular basis of disease 8 38657551
2024 The m6A reader IGF2BP2 promotes esophageal cell carcinoma progression by enhancing EIF4A1 translation. Cancer cell international 8 38724996
2013 Replication of association study between type 2 diabetes mellitus and IGF2BP2 in Han Chinese population. Chinese medical journal 8 24229666

Missed literature

Know a paper Affinage missed for IGF2BP2? Flag it for the maintainers and the community.

No submissions yet.